Multisystem inflammatory syndrome in children: Difference between revisions
(Created page with "==Background== ==Clinical Features== ==Differential Diagnosis== ==Evaluation== ==Management== ==Disposition== ==See Also== ==External Links== ==References== <r...") |
No edit summary |
||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Some individuals may fulfill full or partial criteria for Kawasaki disease but should be reported if they meet the case definition for MIS-C | |||
*Consider MIS-C in any pediatric death with evidence of SARS-CoV-2 infection | |||
==Clinical Features== | ==Clinical Features== | ||
| Line 9: | Line 10: | ||
==Evaluation== | ==Evaluation== | ||
===Case Definition=== | |||
*An individual aged <21 years presenting with fever^, laboratory evidence of inflammation^^, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); AND | |||
*No alternative plausible diagnoses; AND | |||
*Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms | |||
:^Fever >38.0°C for ≥24 hours, or report of subjective fever lasting ≥24 hours | |||
:^^Including, but not limited to, one or more of the following: an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), or interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes and low albumin | |||
| Line 21: | Line 30: | ||
==External Links== | ==External Links== | ||
*https://secureweb.cisco.com/1sVjHLj_qQIGIzsDPe3A65XwAJfefiqVTF5wRLd7qvpQBSyNqf24TEAo8mt-909wYob1eSeWFbcHX50FJYCQ8nZTNQO10r2SkLENZ1HQWHdJk9R55a3288xHeDM9hm5W5dycjyByu84lOV_CMfAQd1Dru8Eim4f9ztUbwBp9refyfB_zTWqMnLDrgWuQa1GNdZDHOtvEKOFPiIjLdDH9tI_Uuu71qnIDJlcBdn4vfGA6RHIzBoeU2PHks1ZQFKgAhEi0EiDo3kXZZbKp5i2fazg/https%3A%2F%2Ftotalwebcasting.com%2Fview%2F%3Ffunc%3DVOFF%26id%3Dnysdoh%26date%3D2020-05-14%26seq%3D1 | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 16:33, 18 May 2020
Background
- Some individuals may fulfill full or partial criteria for Kawasaki disease but should be reported if they meet the case definition for MIS-C
- Consider MIS-C in any pediatric death with evidence of SARS-CoV-2 infection
Clinical Features
Differential Diagnosis
Evaluation
Case Definition
- An individual aged <21 years presenting with fever^, laboratory evidence of inflammation^^, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); AND
- No alternative plausible diagnoses; AND
- Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms
- ^Fever >38.0°C for ≥24 hours, or report of subjective fever lasting ≥24 hours
- ^^Including, but not limited to, one or more of the following: an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), or interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes and low albumin